5 results
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
To compare the efficacy of 7.5 mg/kg of crizanlizumab versus placebo on the annualized rate of VOC leading to healthcare visit, in addition to standard of careTo compare the efficacy of 5.0 mg/kg of crizanlizumab versus placebo on the annualized…
Primary objective: To explore the effect on volume of keloid tissue (mm3), measured by 3D-camera, after three consecutive treatments with electronic jet injector assisted bleomycin delivery, compared with placebo in a split-lesion design.Secondary…
To study the effect of crizanlizumab on the hemodynamics of the cerebral vasculature (CBF and CVR)
To investigate whether on demand dosing using population-based PK-models in VWD patients is reliable and feasible.